Entellus Medical, Inc. (ENTL) Receives Average Recommendation of “Hold” from Analysts

Entellus Medical, Inc. (NASDAQ:ENTL) has received an average recommendation of “Hold” from the ten research firms that are covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, three have issued a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $21.00.

ENTL has been the topic of several recent analyst reports. Canaccord Genuity reiterated a “hold” rating and set a $17.00 target price on shares of Entellus Medical in a research report on Tuesday, October 17th. Piper Jaffray Companies reiterated a “buy” rating and set a $21.00 target price on shares of Entellus Medical in a research report on Tuesday, August 22nd. BidaskClub upgraded Entellus Medical from a “hold” rating to a “buy” rating in a research report on Saturday, August 19th. Finally, Zacks Investment Research upgraded Entellus Medical from a “sell” rating to a “buy” rating and set a $23.00 target price on the stock in a research report on Monday, October 9th.

In other news, VP Timothy B. Petrick sold 2,000 shares of the firm’s stock in a transaction dated Friday, September 22nd. The stock was sold at an average price of $18.00, for a total value of $36,000.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, VP Kevin L. Mensink sold 2,500 shares of the firm’s stock in a transaction dated Friday, October 20th. The stock was sold at an average price of $19.00, for a total value of $47,500.00. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 92,150 shares of company stock worth $1,740,652. Company insiders own 7.70% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in the company. Frontier Capital Management Co. LLC raised its holdings in shares of Entellus Medical by 85.0% in the 2nd quarter. Frontier Capital Management Co. LLC now owns 866,370 shares of the medical technology company’s stock worth $14,347,000 after purchasing an additional 397,953 shares during the period. First Light Asset Management LLC grew its stake in shares of Entellus Medical by 25.7% in the second quarter. First Light Asset Management LLC now owns 512,416 shares of the medical technology company’s stock valued at $8,486,000 after buying an additional 104,919 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Entellus Medical by 14.2% in the second quarter. Vanguard Group Inc. now owns 485,294 shares of the medical technology company’s stock valued at $8,036,000 after buying an additional 60,471 shares in the last quarter. Archon Capital Management LLC grew its stake in shares of Entellus Medical by 34.3% in the second quarter. Archon Capital Management LLC now owns 478,820 shares of the medical technology company’s stock valued at $7,929,000 after buying an additional 122,171 shares in the last quarter. Finally, William Blair Investment Management LLC grew its stake in shares of Entellus Medical by 10.5% in the second quarter. William Blair Investment Management LLC now owns 431,187 shares of the medical technology company’s stock valued at $7,140,000 after buying an additional 40,853 shares in the last quarter. Institutional investors own 70.34% of the company’s stock.

Entellus Medical (NASDAQ ENTL) traded up $0.60 during midday trading on Friday, reaching $17.24. The company had a trading volume of 115,846 shares, compared to its average volume of 131,269. The company has a debt-to-equity ratio of 0.19, a quick ratio of 3.53 and a current ratio of 3.87.

Entellus Medical (NASDAQ:ENTL) last released its earnings results on Thursday, August 3rd. The medical technology company reported ($0.37) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.34) by ($0.03). Entellus Medical had a negative return on equity of 60.10% and a negative net margin of 31.24%. The business had revenue of $22.10 million for the quarter, compared to analysts’ expectations of $21.87 million. During the same quarter last year, the company posted ($0.27) earnings per share. The business’s quarterly revenue was up 18.0% compared to the same quarter last year. analysts predict that Entellus Medical will post -1.62 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This news story was originally published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The correct version of this news story can be viewed at https://ledgergazette.com/2017/11/20/entellus-medical-inc-entl-receives-average-recommendation-of-hold-from-analysts.html.

Entellus Medical Company Profile

Entellus Medical, Inc is a medical technology company. The Company is focused on delivering patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients. Its three core product lines, XprESS Multi-Sinus Dilation Systems, MiniFESS Surgical Instruments, and FocESS Imaging & Navigation, are designed to enable ear, nose and throat (ENT), physicians to perform a range of procedures in the ENT physician office and to simplify operating room-based treatment.

Analyst Recommendations for Entellus Medical (NASDAQ:ENTL)

Receive News & Ratings for Entellus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entellus Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply